argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune Myositis

What happened: Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ALKIVIA trial results for VYVGART in autoimmune myositis, meeting the primary endpoint with clinically meaningful improvement over placebo in both IMNM and dermatomyositis groups. Key numbers: Late breaking oral presentation planned at a Why it matters: The readout adds a potential indication on top of myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, supporting the multi product immunology portfolio case after the Sjogren's setback. Investors will watch for movement toward regulatory filings.

Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ALKIVIA trial results for VYVGART in autoimmune myositis, meeting the primary endpoint with clinically meaningful improvement over placebo in both IMNM and dermatomyositis groups.

The readout adds a potential indication on top of myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, supporting the multi product immunology portfolio case after the Sjogren's setback. Investors will watch for movement toward regulatory filings.